Donor-derived solid malignancies after hematopoietic stem cell transplantation

Abstract

Allogeneic hematopoietic stem cell transplantation is considered to be a potentially therapeutic strategy for various hematopoietic benign diseases and malignancies. The growing number of reports on long-term survivors after hematopoietic stem cell transplantation reveals the major merits of this strategy. However, such cohorts remain at high risk of potential late complications, including the development of secondary solid malignancies. An increasing number of cases of secondary malignancies originated from recipients, donors, or unknown sources has been reported. In this review, we focus on latest clinical evidence of donor-derived solid malignancies after allogeneic hematopoietic stem cell transplantation, postulate related potential mechanisms, and further address novel indications as well as feasible therapeutic and preventive perspectives.